title: Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing.
abstract: The international normalized ratio (INR) can be unreliable in patients with lupus anticoagulants (LACs) or other conditions affecting baseline testing. Alternative methods to assess anticoagulation on warfarin through measures of vitamin K-dependent factor activity by clot based or chromogenic assays may be necessary. In this patient population, the ideal method is unknown. Thirty-six patients stable on warfarin with LAC or unreliable INR testing had an INR, a prothrombin time-based clotting assay for factor II (FII) activity, and a chromogenic assay for factor X (CFX) activity were performed simultaneously. Eighty-nine sets of measurements were obtained of which 83 sets included all three assays. CFX and FII levels were well correlated (r = 0.92) in all patients and in 26 patients with a documented antiphospholipid antibody (r = 0.93). Parallel testing was seen in 99% of FII assays. Sixty-one percent of CFX and 57% of FII were within the therapeutic range. In 32 CFX and FII pairs wherein assessment of anticoagulation was discordant, 16 CFX agreed with INR and 13 FII agreed with INR (McNemar's, χ = 0.14, P = 0.7). The number of times tests were discrepant was not statistically different between CFX and FII (P = 0.36). CFX and FII activity are well correlated in patients that require alternative monitoring of warfarin. Either test can be used in this population.
authors.affiliation: aDivision of Hematology, Oncology, and Transplantation, University of Minnesota bDepartment of Laboratory Medicine and Pathology, University of Minnesota cCTSI Biostatstics, University of Minnesota, Minneapolis, Minnesota, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Baumann Kreuziger
authors.forename: Yvonne H
authors.initials: YH
authors.lastname: Datta
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Johnson
authors.forename: Nicole D
authors.initials: ND
authors.lastname: Zantek
authors.forename: Ryan
authors.initials: R
authors.lastname: Shanley
authors.forename: Mark T
authors.initials: MT
authors.lastname: Reding
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests / Q000379:methods*; D016903:Drug Monitoring / Q000379:methods; D005170:Factor X / Q000378:metabolism*; D005260:Female; D006801:Humans; D019934:International Normalized Ratio / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011516:Prothrombin / Q000378:metabolism*; D011517:Prothrombin Time; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D011516:Prothrombin; D005170:Factor X